Veru (VERU) Other Non-Current Liabilities (2016 - 2026)
Veru (VERU) posted quarterly Other Non-Current Liabilities of $800000.0 for Q1 2026, down 76.22% year-over-year from $3.4 million in Q1 2025, and down 27.44% quarter-over-quarter from $1.1 million in Q4 2025.
Veru (VERU) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Veru (VERU) has reported Other Non-Current Liabilities for 11 consecutive years, with $800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 76.22% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $800000.0 (down 76.22% YoY), while the FY2025 annual figure was $1.4 million, down 69.52% from the prior year.
- Other Non-Current Liabilities fell to $800000.0 in Q1 2026 per VERU's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5.0 million in Q1 2024 and bottomed at $15000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $1.7 million across 5 years, with a median of $951261.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 15040.59% — and 2026, when it slumped 76.22%.
- Veru's Other Non-Current Liabilities stood at $25755.0 in 2022, then rose by 16.28% to $29948.0 in 2023, then jumped by 13517.56% to $4.1 million in 2024, then tumbled by 72.97% to $1.1 million in 2025, then fell by 27.44% to $800000.0 in 2026.
- Business Quant data shows VERU's Other Non-Current Liabilities at $800000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 587,823.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Sep 30, 2023 | 29,948.00 |
| Jun 30, 2023 | 40,111.00 |
| Mar 31, 2023 | 32,933.00 |
| Dec 31, 2022 | 25,755.00 |
| Sep 30, 2022 | 18,577.00 |
| Jun 30, 2022 | 15,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 14,986.00 |
| Sep 30, 2021 | 14,986.00 |
| Jun 30, 2021 | 14,986.00 |